Qiuyun Li’s research while affiliated with Guangxi Medical University and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (5)


Global burden of NRLC. The global incidence number (A) and ASIR (B) of NRLC in 2021; The global deaths number (C) and ASMR(D) of NRLC in 2021.
Regional burden of NRLC. The regional level incidence number (A) and ASIR (B) of NRLC in 2021; The regional level deaths number. (C) and ASMR (D) of NRLC in 2021.
National burden of NRLC. (A)The national level incident cases of NRLC in 2021; (B) The national level ASIR of NRLC in 2021; (C) The national level changes of ASIR of NRLC from 1990 to 2021.
Burden of NRLC by age and sex. The incidence cases number and rates in different level of age and sex.
Burden of NRLC by sociodemographic index. (A) The association between ASDR and SDI of NRLC of 21 GBD regions from 1990 to 2021; (B) The association between ASDR and SDI of NRLC of 204 countries and territory in 2021.
Burden of NASH related liver cancer from 1990 to 2021 at the global, regional, and national levels
  • Article
  • Full-text available

January 2025

·

13 Reads

·

1 Citation

Shuang Li

·

Shuangjiang Li

·

Linjing Guan

·

[...]

·

Guangdong Pan

Background The global burden of non-alcoholic steatohepatitis (NASH)-related liver cancer (NRLC) is increasing, making NASH the fastest-growing cause of liver cancer worldwide. This study presents a comprehensive analysis of NRLC burden at the global, regional, and national levels, further categorized by age, sex, and sociodemographic index (SDI). Method Data on NRLC from the Global Burden of Disease, Injuries, and Risk Factors (GBD) study 2021 were downloaded at global, regional, and national levels. The numbers and age-standardized rates (ASRs) of incidence, mortality, and disability-adjusted life years (DALYs) were analyzed to quantify the global burden of NRLC. Additionally, percentage changes in ASRs were used to identify trends in NRLC from 1990 to 2021. Results Globally, both the number of cases and ASRs for NRLC increased between 1990 and 2021. In 2021, there were 42,291 new cases, 40,925 deaths, and 995,475 DALYs attributed to NRLC. East Asia, South Asia, and Southeast Asia reported the highest absolute case numbers, while Western, Southern, and Eastern Sub-Saharan Africa exhibited the highest ASRs. From 1990 to 2021, Australasia, Southern Latin America, and High-income North America showed the most significant increases in NRLC incidence. Nationally, Mongolia, Gambia, and Mozambique exhibited the highest ASR in 2021.The greatest percentage increases in ASIR occurred in Australia, the United Kingdom, and New Zealand between 1990 and 2021. NRLC incidence rates were higher in men and increased with age, peaking at 80–89 years. Similar patterns were observed for NRLC-related deaths and DALYs. Regionally, ASRs initially declined but then increased as SDI rose. At the national level, ASRs consistently decreased with higher SDI. Conclusion This study highlights the substantial burden of NRLC at global, regional, and national levels. Males and older individuals bear a higher disease burden, and considerable variation exists across different regions and countries. These findings provide critical insights for formulating effective strategies to prevent and manage NRLC.

Download

ldentify potential feature genes and immune cell infiltration of HIRI based on branched-chain amino acid-related genes by machine learning and experimental validation

December 2024

·

2 Reads

Background Branched-chain amino acid metabolism is involved in the pathogenesis of various liver diseases. In this study, we investigate the potential role of branched-chain amino acid metabolism-related genes in the pathogenesis of hepatic ischemia reperfusion (HIRI). Methods The gene Expression profiles of HIRI were obtained from the Gene Expression Omnibu database. To determine the differential expression of branched-chain amino acid metabolism-related genes between HIRI and normal tissues. Then, the GO and KEGG analyses were performed, and the protein-protein interaction network was constructed. Next, the random forest and LASSO algorithms were used to screen hub genes, and machine learning techniques were used to build diagnostic models. immunoinfiltration was analyzed in both HIRI patients and controls and the ceRNA network was established. Finally, quantitative real-time PCR was used to verify the expression of hub gene. Results Based on data set GSE23649, three central DEGs (SLC7A5, SLC1A5, SLC43A2) were determined by the intersection of three machine learning algorithms and used to establish a nomogram that yielded a high predictive performance (area under the curve 0.733−0.922). In the external GSE15480 dataset, AUC value for three key genes is as high as 1.000. Further analysis of nomogram, decision curve and calibration curve also confirme the predictive efficacy of diagnosis. GSEA and GSVA suggest that these three marker genes were involved in multiple pathways associated with HIRI progression. Immunoinfiltration analysis suggest that the proportion of macrophages, neutrophils, aDCs, Treg, and Th1 cells in HIRI group is higher than that in control group, with statistical significance(P<0.05). The ceRNA network demonstrates the complex regulatory relationships among the three hub genes and these mRNA levels were further confirmed in mouse HIRI liver samples. Conclusions Our study have provided a comprehensive understanding of the association between branched-chain amino acid and HIRI, may provide potential target for HIRI treatment and diagnosis. And provide new insights into the mechanisms of HIRI. Graphical Abstract


Identification of PANoptosis-related subtypes, construction of a prognosis signature, and tumor microenvironment landscape of hepatocellular carcinoma using bioinformatic analysis and experimental verification

April 2024

·

13 Reads

·

10 Citations

Background Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide. PANoptosis is a recently unveiled programmed cell death pathway, Nonetheless, the precise implications of PANoptosis within the context of HCC remain incompletely elucidated. Methods We conducted a comprehensive bioinformatics analysis to evaluate both the expression and mutation patterns of PANoptosis-related genes (PRGs). We categorized HCC into two clusters and identified differentially expressed PANoptosis-related genes (DEPRGs). Next, a PANoptosis risk model was constructed using LASSO and multivariate Cox regression analyses. The relationship between PRGs, risk genes, the risk model, and the immune microenvironment was studies. In addition, drug sensitivity between high- and low-risk groups was examined. The expression profiles of these four risk genes were elucidate by qRT-PCR or immunohistochemical (IHC). Furthermore, the effect of CTSC knock down on HCC cell behavior was verified using in vitro experiments. Results We constructed a prognostic signature of four DEPRGs (CTSC, CDCA8, G6PD, and CXCL9). Receiver operating characteristic curve analyses underscored the superior prognostic capacity of this signature in assessing the outcomes of HCC patients. Subsequently, patients were stratified based on their risk scores, which revealed that the low-risk group had better prognosis than those in the high-risk group. High-risk group displayed a lower Stromal Score, Immune Score, ESTIMATE score, and higher cancer stem cell content, tumor mutation burden (TMB) values. Furthermore, a correlation was noted between the risk model and the sensitivity to 56 chemotherapeutic agents, as well as immunotherapy efficacy, in patient with. These findings provide valuable guidance for personalized clinical treatment strategies. The qRT−PCR analysis revealed that upregulated expression of CTSC, CDCA8, and G6PD, whereas downregulated expression of CXCL9 in HCC compared with adjacent tumor tissue and normal liver cell lines. The knockdown of CTSC significantly reduced both HCC cell proliferation and migration. Conclusion Our study underscores the promise of PANoptosis-based molecular clustering and prognostic signatures in predicting patient survival and discerning the intricacies of the tumor microenvironment within the context of HCC. These insights hold the potential to advance our comprehension of the therapeutic contribution of PANoptosis plays in HCC and pave the way for generating more efficacious treatment strategies.


Global burden of acute hepatitis E between 1990 and 2019 and projections until 2030

March 2024

·

21 Reads

·

7 Citations

Liver international: official journal of the International Association for the Study of the Liver

Background and Aims Acute hepatitis E (AHE) is still a public health issue worldwide. Here, we report the global burden of AHE in 204 countries and territories from 1990 to 2019 by age, sex and socio‐demographic index (SDI), and predict the future trends to 2030. Methods Data on AHE were collected from the Global Burden of Diseases, Injuries and Risk Factors Study 2019. The average annual percentage change (AAPC) and joinpoint analysis were used to determine the burden trend. Results In 2019, there were 19.47 million (95% UI, 16.04 to 23.37 million) incident cases of AHE globally, with a 19% increase since 1990. Age‐standardized rate (ASR) of disability‐adjusted life years (DALYs), prevalent and incident cases declined from 1990 to 2019. In 2019, the ASR of incidence, prevalence and DALYs due to HEV infection were highest in the same regions of South Asia for both sexes. Southern Sub‐Saharan Africa presented the highest increases in the ASR for incidence of HEV infection in both males (AAPC = .25) and females (AAPC = .24) from 1990 to 2019. Incident cases are higher in males than females before 55–59 years old. The SDI values were negatively correlated with the age‐standardized DALYs. Between 2019 and 2030, the ASR for incidence and prevalence of HEV for both sexes showed an increasing trend. Conclusions Although the overall ASR of AHE decreased, the burden of AHE remains an underappreciated problem for society. The findings may provide useful information for policymakers to develop appropriate strategies aimed at reducing the burden of AHE.


Citations (2)


... G6PD is the key rate-controlling enzyme performed as an oncogene in bladder, liver, and breast cancer [48,49]. In rodent models, elevated G6PD expression correlates with an increased prevalence and severity of hepatic precancerous conditions, highlighting its pivotal role in the pathogenesis of liver cancer [50,51]. Th2 cells were reported to focus on humoral immunity [52], and inhibit Th1 cells' activity from attenuating the macrophage response [53]. ...

Reference:

Glutathiones’ life in multi-cancers: especially their potential micropetides in liver hepatocellular carcinoma
Identification of PANoptosis-related subtypes, construction of a prognosis signature, and tumor microenvironment landscape of hepatocellular carcinoma using bioinformatic analysis and experimental verification

... Moreover, more severe and chronic forms of hepatitis are able to develop in immunocompromised patients (5). An estimated 20.0 million cases of acute Hepatitis E in 2019 and approximately 44,000 deaths were reported representing 3.3% of all viral hepatitis-related mortality (6). ...

Global burden of acute hepatitis E between 1990 and 2019 and projections until 2030
  • Citing Article
  • March 2024

Liver international: official journal of the International Association for the Study of the Liver